Autor(es):
Urt-Filho, Antonio ; Oliveira, Rodrigo Juliano ; Hermeto, Larissa Correa [UNESP] ; Pesarini, Joao Renato ; David, Natan de ; Cantero, Wilson de Barros ; Falcao, Gustavo ; Marks, Guido ; Milan Brochado Antoniolli-Silva, Andrcia Conceicao
Data: 2018
Identificador Persistente: http://hdl.handle.net/11449/161625
Origem: Oasisbr
Assunto(s): bone marrow; chemotherapy; nephrotoxicity; kidney disease; tissue regeneration; bone marrow; bone marrow; chemotherapy; chemotherapy; nephrotoxicity; nephrotoxicity; kidney disease; kidney disease; tissue regeneration; tissue regeneration
Descrição
Made available in DSpace on 2018-11-26T16:40:43Z (GMT). No. of bitstreams: 0 Previous issue date: 2016-04-01. Added 1 bitstream(s) on 2021-07-15T15:01:28Z : No. of bitstreams: 1 S1415-47572016000200290.pdf: 2702901 bytes, checksum: 6f4dfa0a53318e6fc3b7f3ab1db3a5d4 (MD5)
Mato Grosso do Sul Foundation for the Developmental of Education, Science and Tecnology (Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul FUNDECT)
Acute renal failure (ARF) is an extremely important public health issue in need of novel therapies. The present study aimed to evaluate the capacity of mesenchymal stem cell (MSC) therapy to promote the improvement and recovery of renal function in a preclinical model. Wistar rats were used as the experimental model, and our results show that cisplatin (5mg/kg) can efficiently induce ARF, as measured by changes in biochemical (urea and creatinine) and histological parameters. MSC therapy performed 24h after the administration of chemotherapy resulted in normalized plasma urea and creatinine levels 30 and 45d after the onset of kidney disease. Furthermore, MSC therapy significantly reduced histological changes (intratubular cast formation in protein overload nephropathy and tubular hydropic degeneration) in this ARF model. Thus, considering that current therapies for ARF are merely palliative and that MSC therapy can promote the improvement and recovery of renal function in this model system, we suggest that innovative/alternative therapies involving MSCs should be considered for clinical studies in humans to treat ARF.
Empresa Brasileira Serv Hosp, Hosp Univ Maria Aparecida Pedrossian, Ctr Estudos Celulas Tronco Terapia Celular & Gene, Campo Grande, MS, Brazil
Univ Fed Mato Grosso do Sul, Programa Posgrad Saude & Dev, Regiao Ctr Oeste, Fac Med Dr Helio Mandetta, Campo Grande, MS, Brazil
Univ Fed Mato Grosso do Sul, Ctr Ciencias Biol & Saude, Programa Mestrado Farm, Campo Grande, MS, Brazil
Univ Estadual Paulista, Fac Ciencias Agr & Vet, Programa Posgrad Clin Vet, Jaboticabal, SP, Brazil
Univ Fed Mato Grosso do Sul, Fac Med Dr Helio Mandetta, Campo Grande, MS, Brazil
Univ Estadual Paulista, Fac Ciencias Agr & Vet, Programa Posgrad Clin Vet, Jaboticabal, SP, Brazil
